HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Binod Dhakal, MD, on Developing Controllable CAR T-Cell Therapies for Multiple Myeloma

The associate professor of medicine at Medical College of Wisconsin discussed advantages of the ARC-SparX platform.

“This platform has a lot of potential advantages to address a lot of unmet needs, not only for myeloma, but beyond myeloma and potentially beyond cancers. We're very excited to start off this trial and to enroll patients."

Arcellx has dosed the first patient in their phase 1, open-label clinical trial (NCT04155749) of ACLX-001, a chimeric antigen receptor (CAR) T-cell therapy developed with the company’s ARC-SparX cell therapy platform for the potential treatment of relapsed or refractory multiple myeloma (r/r MM).

The proof of concept, dose-escalation study will assess up to 65 participants in 2 treatment arms: (1) CART-ddBCMA and (2) SPRX001 and ARC-T cells. A matrix escalation of either ARC-T cells, SparX-001, or both may be escalated during the trial depending on pharmacokinetic data.

CGTLive spoke with Binod Dhakal, MD, associate professor of medicine, Medical College of Wisconsin, to learn more about the ARC-SparX platform and the phase 1 study. He discussed the advantages of the platform and the redosable and controllable ACLX-001, in r/r MM.

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma. News release. Arcellx. May 10, 2022. https://www.prnewswire.com/news-releases/arcellx-announces-dosing-of-first-patient-in-its-phase-1-clinical-trial-evaluating-aclx-001-the-first-therapeutic-in-the-dosable-and-controllable-arc-sparx-platform-for-the-treatment-of-patients-with-relapsed-or-refractory-multi-301544169.html